TY  - JOUR
AU  - Pascual, Tomas
AU  - Apellániz-Ruiz, María
AU  - Pernaut, Cristina
AU  - Cueto-Felgueroso, Cecilia
AU  - Villalba, Pablo
AU  - Álvarez, Carlos
AU  - Manso, Luis
AU  - Inglada Perez, Lucia
AU  - Robledo Batanero, Mercedes
AU  - Rodriguez Antona, Cristina
AU  - Ciruelos, Eva
PY  - 2017
DO  - 10.1371/journal.pone.0180192
SN  - 1932-6203
UR  - http://hdl.handle.net/20.500.12105/5275
AB  - PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane....
LA  - eng
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - Breast Neoplasms
KW  - Disease-Free Survival
KW  - Everolimus
KW  - Female
KW  - Genotype
KW  - Humans
KW  - Middle Aged
KW  - Pharmacogenetics
KW  - Prognosis
KW  - Survival Rate
KW  - Treatment Outcome
KW  - Polymorphism, Single Nucleotide
TI  - Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
TY  - journal article
ER  -